drugset
drugset / Trial / NCT03922373

A Study of Benzonatate Soft Capsule in Chinese Healthy Subjects

NCT03922373 ↗

Phase 1 Unknown 40 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Objective to study the pharmacokinetic, safety and efficacy of Single-dose and multiple-dose of benzonatate in Chinese healthy male and female subjects.

Timeline

Start
2018-09-10
Primary completion
2019-02-27
Completion
2019-04-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Benzonatate Small molecule 100 mg —
Subject Benzonatate Small molecule 200 mg —
Subject Benzonatate Small molecule 400 mg —

Indications

No indication recorded.